BioMarin Pharma (BMRN) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $127 at JPMorgan
February 23, 2018 7:27 AM ESTJPMorgan lowered its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $127.00 (from $129.00) while maintaining a Overweight rating.
... MoreBioMarin Pharmaceutical Inc. (BMRN) PT Raised to $100 at Citi Following 4Q
February 23, 2018 7:11 AM ESTCiti raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $100.00 (from $96.00) while maintaining a Buy rating following the company's 4Q. Results were in-line with consensus estimates on the top-line, while the bottom-line was a miss due to tax impact.
The company... More
